Pharmacological management of narcolepsy with and without cataplexy

References

• Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58:1826–1833.
   PubMed Web of Science ®Google Scholar
• Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31:1246–1254.
   PubMed Web of Science ®Google Scholar
• Oberle D, Drechsel-Bäuerle U, Schmidtmann I, et al. Incidence of narcolepsy in Germany. Sleep. 2015;38:1619–1628.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57:2029–2033.
   PubMed Web of Science ®Google Scholar
• Liblau RS, Vassalli A, Seifinejad A, et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14:318–328.
   PubMed Web of Science ®Google Scholar
• Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654–2662.
   PubMed Web of Science ®Google Scholar
• Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res. 2004;13:395–406.
   PubMed Web of Science ®Google Scholar
• AASM: American Academy of Sleep Medicine. ICSD-3: international classification of sleep disorders. 3rd ed. Darien (IL): American Academy of Sleep Medicine; 2014.
   Google Scholar
• Jennum P, Ibsen R, Petersen ER, et al. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13:1086–1093.
   PubMed Web of Science ®Google Scholar
• Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13:1035–1048.
   PubMed Web of Science ®Google Scholar
• Wise MS, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1712–1727.
   PubMed Web of Science ®Google Scholar
• Krahn LE, Hershner S, Loeding LD, et al. Quality measures for the care of patients with narcolepsy. J Clin Sleep Med. 2015;11:335.
   PubMed Web of Science ®Google Scholar
• Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience. 2005;132:1027–1034.
   PubMed Web of Science ®Google Scholar
• Bobak MJ, Weber MW, Doellman MA, et al. Modafinil activates phasic dopamine signaling in dorsal and ventral striata. J Pharmacol Exp Ther. 2016;359:460–470.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148–1154.
   PubMed Web of Science ®Google Scholar
• Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep. 1994;17:S107–12.
   PubMed Web of Science ®Google Scholar
• Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444–451.
   PubMed Web of Science ®Google Scholar
• Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54:1166–1175.
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Rogers AE, Walsleben JA, et al. Health- related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999;22:757–765.
   PubMed Web of Science ®Google Scholar
• Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 2000;1:109–116.
   PubMed Web of Science ®Google Scholar
• Palovaara S, Kivistö KT, Tapanainen P, et al. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam l-hydroxy- lation. Brit J Clin Pharm. 2000;50:333–337.
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Hellriegel ET, et al. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29:613–623.
   PubMed Web of Science ®Google Scholar
• Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22:761–774.
   PubMed Web of Science ®Google Scholar
• Lin J-S, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis. 2008;30:74–83.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12:1068–1075.
   PubMed Web of Science ®Google Scholar
• Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:200–207.
   PubMed Web of Science ®Google Scholar
• Mamelak M, Black J, Montplasir J. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27:1327–1334.
   PubMed Web of Science ®Google Scholar
• The Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1:391–397.
   PubMed Web of Science ®Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29:939–946.
   PubMed Web of Science ®Google Scholar
• Black J, Swick T, Bogan R, et al. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016;24:57–62.
   PubMed Web of Science ®Google Scholar
• Boscolo-Berto R, Viel G, Montagnese S, et al. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012;16:431–443.
   PubMed Web of Science ®Google Scholar
• Alshaikh MK, Tricco AC, Tashkandi M, et al. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med. 2012;8:451–458.
   PubMed Web of Science ®Google Scholar
• Yoss RE, Daly D. Treatment of narcolepsy with Ritalin. Neurology. 1959;9:171–173.
   PubMed Web of Science ®Google Scholar
• Mitler MM, Shafor R, Hajdukovich R, et al. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep. 1986;9:260–264.
   PubMed Web of Science ®Google Scholar
• Honda Y, Hishikawa Y, Takahashi Y. Long-term treatment of narcolepsy with methylphenidate (Ritalin). Curr Ther Res. 1979;25:288–298.
   Web of Science ®Google Scholar
• Leonard BE, McCartan D, White J, et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol. 2004;19:151–180.
   PubMed Web of Science ®Google Scholar
• Shindler J, Schachter M, Brincat S, et al. Amphetamine, mazindol, and fencamfamin in narcolepsy. BMJ. 1985;290:1167–1170.
   PubMed Web of Science ®Google Scholar
• Alvarez B, Dahlitz M, Grimshaw J, et al. Mazindol in long-term treatment of narcolepsy. Lancet Lond Engl. 1991;337:1293–1294.
   PubMed Web of Science ®Google Scholar
• Mayer G, Meier-Ewert K, Hephata K. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol. 1995;18:306–319.
   PubMed Web of Science ®Google Scholar
• Larrosa O, de la Llave Y, Barrio S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep. 2001;24:282–285.
   PubMed Web of Science ®Google Scholar
• Miyagawa T, Kawamura H, Obuchi M, et al. Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial. PLoS One. 2013;8:e53707.
   PubMed Web of Science ®Google Scholar
• Mitler MM, Hajdukovic R, Erman M. Treatment of narcolepsy with methamphetamine. Sleep. 1993;16:306–317.
   PubMed Web of Science ®Google Scholar
• Chen SY, Clift SJ, Dahlitz MJ, et al. Treatment in the narcoleptic syndrome: self assessment of the action of dexamphetamine and clomipramine. J Sleep Res. 1995;4:113–118.
   PubMed Web of Science ®Google Scholar
• Broughton R, Mamelak M. The treatment of narcolepsy- cataplexy with nocturnal gammahydroxybutyrate. Can J Neurological Sci. 1979;6:1–6.
   PubMed Web of Science ®Google Scholar
• Scrima L, Hartman PG, Johnson FH Jr, et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry. 1989;26:331–343.
   PubMed Web of Science ®Google Scholar
• Lammers GJ, Arends J, Declerck AC, et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep. 1993;16:216–220.
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study Group. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25:42–49.
   PubMed Web of Science ®Google Scholar
• US Xyrem Multicenter Study Group. A 12-month, open- label multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26:31–35.
   PubMed Web of Science ®Google Scholar
• Smith M, Parkes JD, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res. 1996;5:S217.
   Google Scholar
• Langdon N, Bandak S, Shindler J, et al. Fluoxetine in the treatment of cataplexy. Sleep. 1986;9:371–372.
   PubMed Web of Science ®Google Scholar
• Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study. Neurology. 1994;44:707–709.
   PubMed Web of Science ®Google Scholar
• Thirumalai SS, Shubin RA. The use of citalopram in resistant cataplexy. Sleep Med. 2000;1:313–316.
   PubMed Web of Science ®Google Scholar
• Poryazova R, Siccoli M, Werth E, et al. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology. 2005;65:967–968.
   PubMed Web of Science ®Google Scholar
• Schachter M, Parkes JD. Fluvoxamine and clomipramine in the treatment of cataplexy. JNNP. 1980;43:171–174.
   PubMed Web of Science ®Google Scholar
• Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol. 1975;32:653–656.
   PubMedGoogle Scholar
• Guilleminault C, Raynal D, Takahashi S, et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand. 1976;54:71–87.
   PubMed Web of Science ®Google Scholar
• Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 1960;21:1–3.
   Google Scholar
• Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with γ-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep. 1986;9:285–289.
   PubMed Web of Science ®Google Scholar
• Black J, Pardi D, Hornfeldt CS, et al. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6:596–602.
   PubMed Web of Science ®Google Scholar
• Roth T, Dauvilliers Y, Guinta D, et al. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2016 Nov 3. Epub ahead of print. DOI:10.1111/jsr.12468
   PubMedGoogle Scholar
• Poryazova R, Tartarotti S, Khatami R, et al. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience. Eur Neurol. 2011;65:175–182.
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Snyder M, Aloe FS, et al. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep. 1992;15:212–216.
   PubMed Web of Science ®Google Scholar
• Kansagra S, Walter R, Vaughn B. Nocturnal temazepam in the treatment of narcolepsy. J Clin Sleep Med. 2013;9:499–500.
   PubMed Web of Science ®Google Scholar
• Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 2009;10:661–663.
   PubMed Web of Science ®Google Scholar
• Schuld A, Kraus T, Haack M, et al. Obstructive sleep apnea syndrome induced by clonazepam in a narcoleptic patient with REM-sleep-behavior disorder. J Sleep Res. 1999;8:321–322.
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281–284.
   PubMed Web of Science ®Google Scholar
• Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32:158–159.
   PubMed Web of Science ®Google Scholar
• Rossetti AO, Heinzer RC, Tafti M, et al. Rapid occurrence of depression following addition of sodium oxybate to modafinil. Sleep Med. 2010;11:500–501.
   PubMed Web of Science ®Google Scholar
• Boivin DB, Montplaisir J, Poirier G. The effects of L-dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol. 1989;12:339–345.
   PubMed Web of Science ®Google Scholar
• Boivin DB, Lorrain D, Montplaisir J. Effects of bromocriptine on periodic limb movements in human narcolepsy. Neurology. 1993;43:2134–2136.
   PubMed Web of Science ®Google Scholar
• Bedard MA, Montplaisir J, Godbout R, et al. Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol. 1989;12:29–36.
   PubMed Web of Science ®Google Scholar
• Abril B, Carlander B, Touchon J, et al. Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? Sleep Med. 2007;8:181–183.
   PubMed Web of Science ®Google Scholar
• Hoque R, Chesson AL. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. 2010;6:79–83.
   PubMed Web of Science ®Google Scholar
• George CF, Feldman N, Inhaber N, et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effects on sleep-disordered breathing. Sleep Med. 2010;11:38–42.
   PubMed Web of Science ®Google Scholar
• Ruoff C, Swick TJ, Doekel R, et al. Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39:1379–1387.
   PubMed Web of Science ®Google Scholar
• Sodium oxybate for treatment of excessive daytime sleepiness and cataplexy in narcolepsy. ClinicalTrials.gov Identifier: NCT02720744. Study ID Number: CLFT218-1501.
   Google Scholar
• Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A. 2004;101:4649–4654.
   PubMed Web of Science ®Google Scholar
• Baier PC, Hallschmid M, Seeck-Hirschner M, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12:941–946.
   PubMed Web of Science ®Google Scholar
• Nagahara T, Saitoh T, Kutsumura N, et al. Design and synthesis of non-peptide, selective orexin receptor 2 agonists. J Med Chem. 2015;58:7931–7937.
   PubMed Web of Science ®Google Scholar
• Arias-Carrión O, Murillo-Rodríguez E. Effects of hypocretin/orexin cell transplantation on narcoleptic- like sleep behavior in rats. PLoS One. 2014;9:e95342.
   PubMed Web of Science ®Google Scholar
• Valko PO, Khatami R, Baumann CR, et al. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol. 2008;255:1900–1903.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, Rivier F, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56:905–908.
   PubMed Web of Science ®Google Scholar
• Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255:1549–1554.
   PubMed Web of Science ®Google Scholar
• Donjacour CE, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res. 2012;21:479–480.
   PubMed Web of Science ®Google Scholar
• Miyata R, Hayashi M, Kohyama J, et al. Steroid therapy ameliorated cataplexy in three children with recent-onset of narcolepsy. Sleep Med. 2016 Sep 29. Epub ahead of print. pii:S1389-9457(16)30103-4. DOI:10.1016/j.sleep.2016.01.024
   PubMed Web of Science ®Google Scholar
• Sarkanen T, Alén R, Partinen M. Transient impact of rituximab in H1N1 vaccination-associated narcolepsy with severe psychiatric symptoms. Neurologist. 2016;21:85–86.
   PubMed Web of Science ®Google Scholar
• Bernard-Valnet R, Yshii L, Quériault C, et al. CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10956–10961. Epub 2016 Sep 12. DOI:10.1073/pnas.1603325113
   PubMed Web of Science ®Google Scholar